Currently, three classes of monoclonal antibodies targeting type 2 inflammation pathways
are available in Italy for the treatment of severe asthma: anti-IgE (Omalizumab), anti-IL-5/anti …

Asthma phenotyping and endotyping are constantly evolving. Currently, several biologic
agents have been developed towards a personalized approach to asthma management …

Severe asthma comprises several heterogeneous phenotypes, underpinned by complex
pathomechanisms known as endotypes. The latter are driven by intercellular networks …

Biologic therapies in asthma are indicated in severe disease, and they are directed against
specific inflammatory modulators that contribute to pathogenesis and severity. Currently …

Introduction In recent years, monoclonal antibodies targeting Type-2 inflammatory pathways
have been developed for severe asthma treatment. However, even when patients are …

The most recent recommendations from the 2020 National Asthma Education and
Prevention Program Update and Global Initiative for Asthma 2021 guide evidence-based …

The first protein‐binding allosteric RNA‐cleaving DNAzyme (RCD) obtained by direct in vitro
selection against eosinophil peroxidase (EPX), a validated marker for airway eosinophilia, is …

The long-term goal of asthma management is to achieve disease control, comprised of the
assessment of two main domains: 1) symptom control and 2) future risk of adverse …

IL-33 is a multifunctional cytokine that mediates local inflammation upon tissue damage. IL-
33 is known to act on multiple cell types including group 2 innate lymphoid cells (ILC2s), Th2 …

Airway mucus is a hydrogel with unique biophysical properties due to its primary water
composition and a small proportion of large anionic glycoproteins or mucins. The …